Company Snapshot
- Ticker
- MRNA
- Name
- MRNA
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 11668811668.799999
- Volume
- 9,214,138
- Avg Volume (3M)
- 10,831,251
MRNA
MRNA
Last update recent
29.92
+0.46
(+1.56%)
Market Cap
11668811668.799999
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 2221000000.000000
- EPS
- -8.07
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- -3116000000.000000
- Net Margin
- -140.3%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- -3.74
- Forward P/E
- None
- P/S
- 5.25
- P/B
- 1.25
- Beta
- None
- Debt / Equity
- 0.08
- Current Ratio
- 3.92
- Return on Equity
- -0.33%
- Return on Assets
- -0.26%
Technicals & Returns
- Distance vs 200 DMA
- 8.66%
- 200 DMA
- 27.53
- Distance vs 50 DMA
- 14.46%
- 50 DMA
- 26.14
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Read more
- Name
- MRNA
- Industry
- Biotechnology
- CEO
- Mr. Stephane Bancel
- Employees
- 5,600
- IPO Date
- 2018-12-07
- Phone
- 617 714 6500
- Address
- None
- Website
- https://www.modernatx.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Va…
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial c…
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More
Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federa…
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold’ rating and $30 price target, implying limited upside, from Jefferies analysts in their...
U.S. Global Investors to continue monthly dividends; highlights strong performance of gold, silver and airline sector
U.S. Global Investors (NASDAQ:GROW) announced that it will maintain its monthly dividend payments, with $0.0075 per share scheduled for January through...